Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-PRE: Cemiplimab vs Standard-of-Care in Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
NCT06568172Phase 3Suspended
- Sponsor
- National Cancer Institute
- Start
- Feb 2025
- Primary completion
- Aug 2031
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 3
01
Overview
A Phase 3 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by National Cancer Institute. Started Feb 2025; status: suspended.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06568172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568172.